FDA warning letter to Empower Pharmacy signals scrutiny of 503A compounders
Law firm analysis outlines how the agency's action against the large compounder could reshape compliance expectations across 503A pharmacies.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 25 13:49 ETSource: Buchanan Ingersoll & Rooney PC
The wire
- 01The FDA issued a warning letter to Empower Pharmacy, prompting legal analysis of what the action means for 503A compounding pharmacies.
- 02Compounders supplying peptide and GLP-1 preparations are a core part of the supply chain readers depend on, and enforcement posture shapes what pharmacies will dispense.
- 03The specific citations and Empower's response are not detailed here; watch for the company's reply and any follow-on FDA action.
From the source
Read at bipc.comFDA Warning Letter to Empower Pharmacy and What It Means for 503A Compounding Pharmacies
